A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate time to progression in eligible patients
with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus
when treated with the concomitant chemoradiotherapy regimen of bevacizumab/5-fluorouracil
(5-FU)/hydroxyurea/radiation therapy (B-FHX) in comparison to 5-fluorouracil hydroxyurea
(FHX) alone.